ENGOT cx22 Trofuse-036

About this trial

Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body.

Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells.

The goals of this study are to learn:

About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given together, and
If people who receive sac-TMT and pembrolizumab, with or without bevacizumab, live longer overall or without their cancer getting worse as compared to those who receive standard treatment

Patient Profile

The key inclusion criteria. Patients who..

* have cervical cancer that has returned or spread to other parts of the body after treatment and is not treatable by surgery
and/or radiation.
*are at least 18 years old.
* have a particular biomarker called PD-L1

Where’s this trial being run?

Cork University Hospital, St James’s Hospital, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	ENGOT cx22 Trofuse-036
Number:	25-37
Full Title:	A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

Principal Investigator:	Prof. Cadoo (SJH), Prof.Brennan (MMUH) and Dearbhaile Collins (CUH)
Type:	Collaborative
Sponsor:	MSD
Recruitment Started:	Global: Jan 26 Ireland: May 26

Global Recruitment Target:	1023
Ireland Recruitment Target:	10